Activin A more prominently regulates muscle mass in primates than does GDF8
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Growth and differentiation factor 8 (GDF8) is a TGF-β superfamily member, and negative regulator of skeletal muscle mass. GDF8 inhibition results in prominent muscle growth in mice, but less impressive hypertrophy in primates, including man. Broad TGF-β inhibition suggests another family member negatively regulates muscle mass, and its blockade enhances muscle growth seen with GDF8-specific inhibition. Here we show that activin A is the long-sought second negative muscle regulator. Activin A specific inhibition, on top of GDF8 inhibition, leads to pronounced muscle hypertrophy and force production in mice and monkeys. Inhibition of these two ligands mimics the hypertrophy seen with broad TGF-β blockers, while avoiding the adverse effects due to inhibition of multiple family members. Altogether, we identify activin A as a second negative regulator of muscle mass, and suggest that inhibition of both ligands provides a preferred therapeutic approach, which maximizes the benefit:risk ratio for muscle diseases in man.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and others have previously demonstrated that growth differentiation factor-8 (GDF8; also known as myostatin) and activin A (ActA) are the two major ligands mediating the muscle-minimization actions of ActRIIA/B receptors22,26–30.”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“combining these blocking antibodies results in much greater increases in muscle than either of the antibodies individually, with dual blockade matching the muscle growth induced by broader ActRIIA/B pathway blockade in both mice and non-human primates (NHPs)28,31”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“The function of MSTN in muscle is at least partially redundant with that of another TGF-β family member, activin A (13–16).”
From Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight (2020) · cites this paper as [16]
In the citing paper
“However, this effect on glucose tolerance was not observed in mice treated with antibodies specific to two ActRII ligands, GDF-8 and activin A, suggesting the potential involvement of additional ActRII ligands in the regulation of glucose homeostasis [36].”
From Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism (2024) · cites this paper as [36]
In the citing paper
“Notably, administration of a soluble ActRIIB fragment impaired glucose tolerance in lean mice, which was correlated with increased spleen and pancreas weights [36].”
From Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism (2024) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Loffredo, F. S., Steinhauser, M. L., Jay, S. M., Gannon, J., Pancoast, J. R., Yalamanchi, P., Sinha, M., Dall’Osso, C., Khong, D., Shadrach, J. L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.015 · Cited by 948
Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W. S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.011 · Cited by 940
Functional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831
Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle
Sinha, M., Jang, Y. C., Oh, J., Khong, D., Wu, E. Y., Manohar, R., Miller, C., Regalado, S. G., Loffredo, F. S., Pancoast, J. R., et al. (2014) · Science · doi:10.1126/science.1251152 · Cited by 824
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
David, L., Mallet, C., Mazerbourg, S., Feige, J.-J., & Bailly, S. (2007) · Blood · doi:10.1182/blood-2006-07-034124 · Cited by 708
Research works printed but not linked: 1
- Schwarzkopf, M., Coletti, D., Marazzi, G. & Sassoon, D. Chronic p53 leads to skeletal muscle atrophy and muscle stem cell perturbation. Basic Appl. Myol. 18, 131–138 (2008).
Cited by
Sarcopenia, osteoporosis and frailty
Gielen, E., Dupont, J., Dejaeger, M., & Laurent, M. R. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155638 · Cited by 258
ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension
Yung, L.-M., Yang, P., Joshi, S., Augur, Z. M., Kim, S. S. J., Bocobo, G. A., Dinter, T., Troncone, L., Chen, P.-S., McNeil, M. E., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz5660 · Cited by 248
“GDF8 is highly homologous to GDF11 (~90%) (33) and overlaps in function with GDF11 and activin A in regulating muscle mass and myocyte hypertrophy based on genetic loss-of-function and pharmacologic experiments (34, 35).”
BackgroundActivin A in Mammalian Physiology
Bloise, E., Ciarmela, P., Dela Cruz, C., Luisi, S., Petraglia, F., & Reis, F. M. (2019) · Physiological Reviews · doi:10.1152/physrev.00002.2018 · Cited by 199
“Activin A regulates muscle contractile properties (468), muscle force production (219), and muscle mitochondrial oxidative phosphorylation (357).”
BackgroundMolecular Mechanisms of Skeletal Muscle Hypertrophy
Schiaffino, S., Reggiani, C., Akimoto, T., & Blaauw, B. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200568 · Cited by 157
Pathophysiological mechanisms leading to muscle loss in chronic kidney disease
Wang, X. H., Mitch, W. E., & Price, S. R. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00498-0 · Cited by 170
Metadata
- Authors
- Latres, E., Mastaitis, J., Fury, W., Miloscio, L., Trejos, J., Pangilinan, J., Okamoto, H., Cavino, K., Na, E., Papatheodorou, A., Willer, T., Bai, Y., Hae Kim, J., Rafique, A., Jaspers, S., Stitt, T., Murphy, A. J., Yancopoulos, G. D., & Gromada, J.
- Affiliations
- Regeneron (United States) (US)
- Corresponding author
- Gromada, Jesper
- ORCID
- Venue
- Nature Communications
- Published
- 2017-04-28
- Volume
- 8
- Issue
- 1
- Pages
- 15153-15153
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5414365
- OpenAlex
- W2609426395
- Semantic Scholar
- 2e417ec4d417ebe167247c3466c130be75b2cef3
- Cited by
- 185
- References
- 65
- Citations by year
- 2026: 22 · 2025: 12 · 2024: 22 · 2023: 19 · 2022: 17 · 2021: 29 · 2020: 31 · 2019: 20 · 2018: 11 · 2017: 2
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Physical Performance
- Keywords
- activin A, myostatin, skeletal muscle mass, muscle hypertrophy, TGF-beta superfamily, muscle growth, muscle force production, primates
- MeSH terms
- Animals, Antibodies, Monoclonal, Dexamethasone, Humans, Hypertrophy, Isometric Contraction, Macaca fascicularis, Male, Mice, Inbred C57BL, Muscle Hypotonia, Body Mass Index, Mice, SCID, Muscle, Skeletal, Activins, Activin Receptors, Type II, Mice, Rats, Myostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activin A more prominently regulates muscle mass in primates than does GDF8. https://app.cochat.ai/papers/10.1038/ncomms15153
- The paper
- Latres, E., Mastaitis, J., Fury, W., Miloscio, L., Trejos, J., Pangilinan, J., Okamoto, H., Cavino, K., Na, E., Papatheodorou, A., Willer, T., Bai, Y., Hae Kim, J., Rafique, A., Jaspers, S., Stitt, T., Murphy, A. J., Yancopoulos, G. D., & Gromada, J. (2017). Activin A more prominently regulates muscle mass in primates than does GDF8. Nature Communications. https://doi.org/10.1038/ncomms15153
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.